pT2期直肠癌播散与复发模式的系统综述与荟萃分析:对器官保留放疗靶区设计的启示
该系统综述与荟萃分析旨在明确pT2期直肠癌远端系膜内播散、远端壁内播散及侧方淋巴结转移风险,并汇总器官保留后的区域复发模式,据此提出临床靶区勾画规则;在8例患者中的计划研究显示,新规则使计划靶区平均相对缩小18%,并更好地保护危及器官。
要点
- 远端系膜内播散>1 cm的发生率为1.9%(95%CI:0.4-5.4%),最大范围1.3 cm。
- 远端壁内播散>0.5 cm的发生率为4.7%(95%CI:1.3-11.5%),最大范围0.8 cm。
- 肿瘤位于或低于腹膜反折时侧方淋巴结转移率为8.2%(95%CI:6.7-9.9%),高于腹膜反折的肿瘤为0%。
核心结论
- 该荟萃分析提示,cT2期肿瘤的临床靶区应小于当前针对晚期癌症设计的指南范围。
研究设计与样本
- 系统综述与荟萃分析,纳入报告pT2期直肠癌远端系膜内播散、远端壁内播散、侧方淋巴结转移及器官保留后区域复发模式的研究。
- 另在8例患者中开展计划研究,比较按所提规则与按当前晚期癌症指南勾画所得剂量-体积参数。
主要发现
- 远端系膜内播散>1 cm的发生率为1.9%(95%CI:0.4-5.4%),最大范围1.3 cm。
- 远端壁内播散>0.5 cm的发生率为4.7%(95%CI:1.3-11.5%),最大范围0.8 cm。
- 肿瘤位于或低于腹膜反折时侧方淋巴结转移率为8.2%(95%CI:6.7-9.9%),高于腹膜反折的肿瘤为0%。
- 观察等待后单纯区域淋巴结复发率为1.0%(95%CI:0.5-1.7%),术前放疗加局部切除后为2.1%(95%CI:1.2-3.4%)。
- 按所提规则勾画使计划靶区平均相对缩小18%,并更好地保护危及器官。
关键数值与推荐
- 靶区下界距肿瘤1.5 cm以覆盖远端系膜内播散,或1 cm以覆盖远端壁内播散,取两者中更靠尾侧者。
- 靶区上界位于S2/S3椎间隙。
- 对于位于或低于腹膜反折的肿瘤,临床靶区应包括侧方淋巴结。
临床怎么用
- 作者提出上述临床靶区勾画规则,供cT2期直肠癌器官保留放疗靶区设计参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are no guidelines on clinical target volume (CTV) delineation for cT2 rectal cancer treated with organ preservation. MATERIALS AND METHODS: A systematic review and meta-analysis were performed to determine the extent of distal mesorectal (DMS) and distal intramural spread (DIS), the risk of lateral lymph node (LLN) metastases in pT2 tumours, and regional recurrence pattern after organ preservation. RESULTS: The rate of DMS > 1 cm was 1.9% (95% CI: 0.4-5.4%), maximum extent: 1.3 cm. The rate of DIS > 0.5 cm was 4.7% (95% CI: 1.3-11.5%), maximum extent: 0.8 cm. The rate of LLN metastases was 8.2% (95% CI: 6.7-9.9%) for tumours below or at peritoneal reflexion and 0% for higher tumours. Regional nodal recurrences alone were recorded in 1.0% (95% CI: 0.5-1.7%) of patients after watch-and-wait and in 2.1% (95% CI: 1.2-3.4%) after preoperative radiotherapy and local excision. Thus, the following rules for CTV delineation are proposed: caudal border 1.5 cm from the tumour to account for DMS or 1 cm to account for DIS, whichever is more caudal; cranial border at S2/S3 interspace; inclusion of LLN for tumours at or below peritoneal reflexion. A planning study was performed in eight patients to compare dose-volume parameters obtained using these rules to that obtained using current guidelines for advanced cancers. The proposed rules led to a mean 18% relative reduction of planning target volume, which resulted in better sparing of organs-at-risk. CONCLUSION: This meta-analysis suggests a smaller CTV for cT2 tumours than the current guidelines designed for advanced cancers.
引用
- Socha J, Pietrzak L, Zawadzka A, et al. A systematic review and meta-analysis of pT2 rectal cancer spread and recurrence pattern: Implications for target design in radiation therapy for organ preservation. Radiother Oncol. 2019. PMID: 30935577. doi:10.1016/j.radonc.2018.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。